Post by Siegfried

Developing a new medicine is a complex journey, and early oral dosage form decisions can make or break development speed. From flexible first‑in‑human dosing to understanding API properties, solubility, stability, and excipient compatibility, the right early‑stage strategy reduces risk and accelerates progress toward Phase 1. Markus Weigandt explores how thoughtful early formulation lays the scientific foundation for smoother scale‑up and faster clinical advancement: https://lnkd.in/efm4Bk8R